Talaris Therapeutics, Inc. TALS
We take great care to ensure that the data presented and summarized in this overview for Talaris Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TALS
Top Purchases
Top Sells
About TALS
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Insider Transactions at TALS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 21
2024
|
Sandeep Chidambar Kulkarni CEO |
BUY
Open market or private purchase
|
Indirect |
1,779
+20.26%
|
$24,906
$14.85 P/Share
|
|
Aug 16
2024
|
Sandeep Chidambar Kulkarni CEO |
BUY
Open market or private purchase
|
Indirect |
5,221
+50.0%
|
$67,873
$13.79 P/Share
|
|
Jan 29
2024
|
Mark Mcdade Director |
BUY
Open market or private purchase
|
Indirect |
100,000
+18.23%
|
$3,200,000
$32.5 P/Share
|
|
Nov 17
2023
|
Sandeep Chidambar Kulkarni CEO |
BUY
Open market or private purchase
|
Direct |
4,000
+0.55%
|
$64,000
$16.99 P/Share
|
|
Nov 17
2023
|
Parvinder Thiara Director |
BUY
Open market or private purchase
|
Direct |
1,000
+1.18%
|
$17,000
$17.31 P/Share
|
|
Oct 27
2023
|
Caley Castelein Director |
BUY
Open market or private purchase
|
Direct |
15,800
+2.97%
|
$221,200
$14.55 P/Share
|
|
Oct 26
2023
|
Sandeep Chidambar Kulkarni CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+0.68%
|
$60,000
$12.25 P/Share
|
|
Oct 25
2023
|
Caley Castelein Director |
BUY
Open market or private purchase
|
Direct |
4,200
+0.83%
|
$50,400
$12.07 P/Share
|
|
Oct 25
2023
|
Parvinder Thiara Director |
BUY
Open market or private purchase
|
Direct |
2,000
+2.36%
|
$24,000
$12.12 P/Share
|
|
Oct 24
2023
|
Sandeep Chidambar Kulkarni CEO |
BUY
Open market or private purchase
|
Direct |
4,650
+0.64%
|
$46,500
$10.68 P/Share
|
|
Oct 24
2023
|
Aaron Kantoff Director |
BUY
Open market or private purchase
|
Direct |
7,500
+14.18%
|
$82,500
$11.86 P/Share
|
|
Oct 24
2023
|
Parvinder Thiara Director |
BUY
Open market or private purchase
|
Direct |
5,000
+5.83%
|
$50,000
$10.66 P/Share
|
|
Oct 19
2023
|
Sapna Srivastava Director |
BUY
Grant, award, or other acquisition
|
Direct |
518
+50.0%
|
-
|
|
Oct 19
2023
|
Parvinder Thiara Director |
BUY
Grant, award, or other acquisition
|
Direct |
75,782
+50.0%
|
-
|
|
Oct 19
2023
|
Sandeep Chidambar Kulkarni CEO |
BUY
Grant, award, or other acquisition
|
Direct |
716,085
+50.0%
|
-
|
|
Oct 19
2023
|
Mark Mcdade Director |
BUY
Grant, award, or other acquisition
|
Direct |
518
+50.0%
|
-
|
|
Oct 19
2023
|
Mark Mcdade Director |
BUY
Grant, award, or other acquisition
|
Indirect |
348,431
+50.0%
|
-
|
|
Oct 19
2023
|
W Bradford Middlekauff CBO, GC and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
69,201
+50.0%
|
-
|
|
Oct 19
2023
|
Caley Castelein Director |
BUY
Grant, award, or other acquisition
|
Indirect |
458,039
+50.0%
|
-
|
|
Oct 19
2023
|
Caley Castelein Director |
BUY
Grant, award, or other acquisition
|
Direct |
496,519
+50.0%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 112K shares |
|---|